截至2025年3月31日 10:25，国企共赢ETF(159719)上涨0.07%，最新价报1.5元，盘中成交额已达120.15万元。 拉长时间看，截至2025年3月28日，国企共赢ETF近1年累计上涨3.88%。 规模方面，国企共赢ETF近半年规模增长1349.41万元，实现显著增长，新增规模位居可比基金1/3。 份额方面，国企共赢ETF近半年份额增长2100.00万份，实现显著增长，新增份额位居可比基金1/3。 日前，国务院国资委相关负责人在中国电动汽车百人会论坛上表示，下一步将对整车央企进行战略性重组，提高产业集中度。国务院国资委表示，战略性重 组的目标是集中央企的研发制造和市场等优势资源，打造具有全球竞争力、拥有自主核心技术，引领智能网联变革的世界一流汽车集团。此外，还将鼓励央 企加大其他合作。 国企共赢ETF(159719)紧密跟踪富时中国国企开放共赢指数，指数由100只成分股构成，包括80个A股公司和20个在香港上市的中国公司。该指数前十大成分 股均为"中字头"股票，包括中国石油、中国石化、中国建筑、中国移动（A、H股）、中国铁建、中国海油、中国中铁、中国海洋石油、中国神华。 大湾区ETF(512 ...

3月31日，三大股指早盘窄幅下跌，而国企红利板块小幅上涨。截至上午10:00，国企红利ETF(159515)涨0.37%。相关成分股中，唐山港涨2.39%、 中远海控涨1.18%、中国石化涨0.52%，山煤国际、中国神华、冀中能源等小幅跟涨。 近日，A股2024年年报披露逐渐进入高峰期，上市公司分红呈现出诸多积极变化。一是分红规模创下新高。据中国证监会统计，2024年沪深上市 公司分红达到2.4万亿元，分红金额创历史新高。同时分红公司数量占年末上市公司数量比例达73.3%，较上年提升7.4个百分点。二是分红诚意持 续提升。2024年，A股上市公司平均股利支付率、股息率双双提升，达近15年来最高水平。三是分红行为更加稳定。2024年，连续5年分红的上市 公司超过1800家，占上市满5年的上市公司数量的40%；近800家上市公司连续10年分红，占上市满10年的上市公司数量的28%。 展望后市，华泰证券表示，今年以来由于科技板块受到全球投资者的持续关注，导致高股息板块的表现相对较弱。然而，随着月末海外市场的不 确定性增加，高股息板块开始展现出其防御性的特点，有望吸引寻求避险资金的关注。 国企红利指数(代码00082 ...

Investment Rating - The investment rating for the company is "Buy (Maintain)" [5] Core Views - The company has shown significant growth in revenue and profit, with a 9.24% increase in revenue to 30.063 billion yuan and a 52.92% increase in net profit to 1.327 billion yuan in 2024. The company is expected to continue this growth trajectory, with projected net profits of 2.123 billion yuan, 2.812 billion yuan, and 3.733 billion yuan for 2025, 2026, and 2027 respectively [9][10] - The company is well-positioned in the engineering machinery industry, with strong market shares in loader and excavator segments, and is experiencing rapid growth in emerging markets and new product lines such as electric loaders and mining machinery [2][3][4] Summary by Sections Financial Performance - In 2024, the company achieved a gross margin of 22.5%, up 1.68 percentage points year-on-year, and a net margin of 4.61%, up 1.19 percentage points year-on-year. However, in Q4 2024, the gross margin decreased to 19.38% and the net margin to 0.4% [1] - The company’s revenue for 2024 was 30.063 billion yuan, with a year-on-year growth of 9.2%, and the net profit was 1.327 billion yuan, reflecting a year-on-year growth of 52.9% [10] Market Position - The company maintains the largest market share in the domestic loader market and has seen rapid growth in sales of autonomous and smart loader products. The global sales of electric loaders increased by 194%, maintaining a leading market position [2] - The excavator business outperformed the industry growth rate by 27 percentage points, with overall profitability improving and a 48% increase in profits [2] Emerging Business Segments - The company’s new business segments, including mining machinery, aerial work platforms, and agricultural machinery, are rapidly developing, with mining machinery sales increasing by over 60% year-on-year [3] - The agricultural machinery segment has made significant advancements, including the successful launch of a 200-horsepower power-shift tractor, marking a breakthrough in technology [3] Global Expansion - The company is actively expanding its overseas market presence, with overseas sales growth outpacing the industry by 22 percentage points and overseas revenue increasing by 20.05% year-on-year [4] - The electric product line has become a new growth driver, with revenue from electric products increasing by over 380% [4]

长按即可参与 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 山行 来源：雪球 很多人说 ， 煤炭是周期股 ， 这没错 。 不过周期股的景气度高点和低点各有不同 ， 有些差的 公司是低点亏损累累 ， 甚至破产 ， 而神华不是 。 中国神华历史上从来都是盈利的 ， 即使在 全行业亏损的时候 ， 他也有161亿净利润 ， 这还是当年提了57.7亿资产减值损失之后的 。 看图 ， 中国神华盈利的周期只有赚多赚少 ， 没有亏损 ， 微利都不可能 。 这里面原因很清楚 ， 一是神华采煤 ， 运煤 ， 煤化工 ， 煤电一体化 ， 用传统说话叫打通产业链 ， 用现在说法 叫形成了 " 生态圈 " 。 二是煤炭是资源 ， 资源就如同人的智商 ， 天然决定了三六九等 ， 好 的资源很大程度上决定了成本低 ， 效率高 。 吨煤开采成本108元 ， 远低于同行水平 ， 且基本 械化开采 ， 安全事故等极低 ， 这是天然的护城河 。 图一 ， 中国神华历年净利润 2016年年报中国神华来了个600亿的豪华派息 。 实际上 ， 神华历史上派息从未低于40%的水 平 ， 历史上有过三次特别派 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 11.22 RMB based on a 17x PE for 2025 [3]. Core Views - The company is expected to benefit from state-owned enterprise reforms and improved profitability, with a projected net profit margin increase of 3.2 percentage points from 2022 to Q3 2024 [1]. - Domestic demand for excavators is anticipated to recover, with a forecast of 100,500 units sold in 2024, representing an 11.7% year-on-year increase [1]. - The mining machinery segment is poised for significant growth, with expected revenues of 8.501 billion, 11.552 billion, and 15.445 billion RMB for 2024, 2025, and 2026 respectively, reflecting growth rates of 45.1%, 35.9%, and 33.7% [2]. Summary by Sections Investment Logic - The company has optimized its revenue structure by merging with Xugong Limited, incorporating high-margin products such as earthmoving and mining machinery [1]. - The focus on improving gross margins and reducing risk exposure has been emphasized through market-oriented executive compensation and stock incentives linked to ROE and net profit [1]. - The company is expected to see a revenue growth rate of -2.7%, +11.5%, and +14.7% from 2024 to 2026 [1]. Mining Machinery - The global open-pit mining machinery market exceeds 37 billion USD, with a projected 3% year-on-year increase in demand for 2024 [2]. - The company has secured nearly 4 billion RMB in orders from top foreign clients, indicating a potential breakout period for its mining machinery segment [2]. - The company’s mining machinery revenue is expected to grow significantly, with projections of 8.501 billion, 11.552 billion, and 15.445 billion RMB for 2024, 2025, and 2026 respectively [2]. Profit Forecast, Valuation, and Rating - The company is projected to achieve revenues of 90.317 billion, 100.662 billion, and 115.458 billion RMB from 2024 to 2026, with corresponding net profits of 5.946 billion, 7.799 billion, and 10.263 billion RMB [3]. - The expected PE ratios for the same period are 19, 14, and 11 times respectively [3].

Market Overview - On March 7, 2025, the A-share market showed a trend of oscillation and correction, with all three major indices closing lower. The Shanghai Composite Index fell by 0.25% to 3372.55 points, the Shenzhen Component Index decreased by 0.5% to 10843.73 points, and the ChiNext Index experienced the largest drop, closing at 2205.31 points, indicating significant short-term adjustment pressure on technology growth stocks [1][2]. Market Factors - During the Two Sessions, there was a dense release of policy signals, but the market remains cautious regarding the implementation of specific details. Additionally, external disturbances such as a significant drop in U.S. tech stocks (Nasdaq down 2.61%) and the European Central Bank's interest rate cuts have led to a decrease in global risk appetite, putting pressure on the A-share technology sector [2]. Sector Analysis Strong Performing Sectors - The non-ferrous metals sector led the market, with companies like Huayu Mining, Hunan Gold, and Zhuhai Group hitting the daily limit. The price of antimony products surged, with antimony prices reaching 183,000 yuan/ton on March 7, up approximately 28.87% from 142,000 yuan/ton in early February. This reflects strong demand growth for antimony products [3]. - The AI agent concept saw a boost from the release of the first general-purpose agent application "ManusAI," with stocks like Newcap and Dahua Technology hitting the daily limit. The market anticipates that AI technology is entering the engineering implementation phase, supported by increasing demand for computing power [3]. Weak Performing Sectors - The solid-state battery sector faced declines, with companies like Shanghai Xiba and Delong Co. dropping over 8%. The market is skeptical about the commercialization progress of the technology, leading funds to shift towards more certain cyclical and technology sectors [4]. - The real estate and financial sectors showed weak performance due to economic slowdown and policy regulation, reflecting market caution towards traditional industries [5]. Market Outlook - In the short term, caution is advised, with a focus on policy and performance verification. The State-owned Assets Supervision and Administration Commission has emphasized the need for value reassessment of central enterprises, and the central bank's liquidity easing stance may make undervalued blue-chip stocks a safe haven. The upcoming quarterly report season may pose risks for high-profile sectors like artificial intelligence, which could face performance verification pressure [6]. - In the medium to long term, three main lines of focus are suggested: 1. Technology growth sectors, particularly AI, computing power, and robotics, which may see a new round of market activity if innovations like Manus AI continue to materialize [7]. 2. Consumer recovery and high-end manufacturing, with sectors like automotive parts and non-ferrous metals benefiting from domestic demand recovery and global supply chain restructuring [7]. 3. Policy-driven opportunities in areas such as information technology innovation, state-owned enterprise reform, and "China Special Valuation" themes, where undervalued central enterprises may experience valuation recovery [7].

结构性分化，把握龙头配置价值 ——中药行业2025年2月月报 长城证券产业金融研究院 分析师：刘鹏 执业证书编号：S1070520030002 邮箱：liupeng@cgws.com 分析师：袁紫馨 执业证书编号：S1070122080041 邮箱：yuanzixin@cgws.com 评级：强大于市（维持） 2025.03.03 01 核心观点 核心观点 1、 2024年 中 药 行 业分 化加大 ，头部 效应凸 显，竞 争格局 有望重 塑 2024年多因素影响行业竞争局，头部企业优势集中，华润系（华润三九、东阿阿胶、昆药集团、江中药业）、片仔癀名贵 OTC龙头、 奇 正藏药 院内贴 膏龙头 通过品 牌壁垒 和渠道 优势普 遍实现 稳健增 长，中 小企业 受成本 端压力 、集采 政策、 医保控 费、消费 疲软等 因素共 振 陷 入 亏 损 或利润 同比下 滑，行 业整体 承压， 2025年 业 绩 压 力减弱 下弹性 有望释 放 2、 估 值 与复盘 • 2月中药板块下跌1.15%， 大 幅 跑输 沪深300和 SW 医 药 生 物指数 ，主要 系科技 成长股 资金虹 吸效应 及"AI+医 疗" 关 注 景 ...

Core Viewpoint - The government work report emphasizes a stable yet progressive economic approach, maintaining a GDP growth target of around 5% and a budget deficit target of approximately 4%, indicating a proactive fiscal policy and a moderately loose monetary policy aimed at promoting the healthy development of the real estate and stock markets [2][3]. Group 1: Economic Policy - The fiscal policy is set to be more aggressive, with a total new government debt scale of 11.86 trillion yuan, an increase of 2.9 trillion yuan from the previous year [2]. - The monetary policy will focus on optimizing tools to support the real estate and stock markets [2]. - The budget deficit target of around 4% is a record high, with specific allocations for long-term special bonds and local special bonds being raised [2]. Group 2: Domestic Demand Expansion - The primary task for 2025 is to expand domestic demand, particularly addressing the consumption shortfall [2]. - Key measures include issuing 300 billion yuan in ultra-long special bonds for "old-for-new" exchanges and promoting new types of consumption in digital, green, and intelligent sectors [2]. Group 3: Technological Development - The focus on new productive forces emphasizes the digital economy and advanced manufacturing, with new industry priorities including biomanufacturing, quantum technology, embodied intelligence, and 6G [3]. - The report highlights the importance of digital transformation and the cultivation of digital service providers [3]. Group 4: Capital Market Reform - The report outlines reforms aimed at increasing medium- and long-term capital inflows into the market, along with optimizing IPO and merger and acquisition processes [3]. Group 5: Real Estate Policy - New measures in real estate include reducing restrictive policies and granting local authorities greater autonomy in managing existing housing stock [3]. Group 6: Population and Social Policies - The report addresses community-based elderly care and mentions the introduction of childcare subsidies [4]. Group 7: State-Owned Enterprise Reform - The establishment of a strategic mission evaluation system for state-owned enterprises is highlighted [5].

Investment Rating - The report assigns an "Outperform" rating to the company, with a reasonable valuation range of 9.38 to 11.39 CNY per share, corresponding to a PE ratio of 14 to 17 times for 2025 [4][6]. Core Insights - The company is a leading player in the domestic engineering machinery sector, with a comprehensive product portfolio including cranes, excavators, loaders, rollers, and concrete machinery. It ranks fourth globally and first in China with a sales revenue of 12.964 billion USD in 2023 [1][17]. - The domestic market is stabilizing, with expectations for a recovery in demand driven by equipment replacement cycles and supportive government policies. The overseas market presents significant growth opportunities, with a compound annual growth rate (CAGR) of 43.84% in excavator exports from 2015 to 2023 [2][4]. - The company's competitive edge is enhanced through state-owned enterprise reforms and an expanding international presence, with overseas revenue increasing from 8.26% in 2020 to 40.09% in 2023 [3][4]. Summary by Sections Company Overview - The company is recognized as a leader in the engineering machinery industry, with a strong backing from its controlling shareholder, Xugong Group. It has achieved significant milestones, including the acquisition of key assets and the establishment of a global marketing network [1][33]. Financial Performance - In 2023, the company reported revenues of 92.848 billion CNY, a slight decrease of 1.03% year-on-year, while net profit attributable to shareholders increased by 23.51% to 5.326 billion CNY [5][43]. - The forecast for net profit from 2024 to 2026 is projected to be 6.309 billion CNY, 7.961 billion CNY, and 10.211 billion CNY, respectively, indicating a steady growth trajectory [4][5]. Market Dynamics - The global engineering machinery market was valued at 243.4 billion USD in 2023, with China’s market share increasing from 13.4% in 2013 to 17.2% in 2023 [2][66][67]. - The domestic market is expected to stabilize due to infrastructure investments and a recovery in real estate, which are crucial for the demand for engineering machinery [70]. Competitive Landscape - The competitive landscape remains stable, with leading companies maintaining their market positions. The company ranks fourth globally, with significant market shares in various machinery segments [67][68]. Future Outlook - The company is well-positioned for future growth, driven by ongoing reforms, international expansion, and a focus on high-margin products. The expected recovery in domestic demand and continued growth in overseas markets are key factors for its performance [3][4][43].

Investment Rating - The report maintains a strong investment rating for the biopharmaceutical industry, particularly for the traditional Chinese medicine (TCM) sector, which is expected to benefit from multiple factors in 2025 [2]. Core Insights - The TCM sector is anticipated to experience a gradual reduction in performance pressure in 2025, driven by factors such as improved earnings, favorable policies, decreasing costs, rising demand, and consolidation within the industry [4][6]. - The report identifies five main investment opportunities within the TCM sector, including high-end OTC products, state-owned enterprise reforms, hospital-based TCM, dividend-paying assets, and turnaround situations for struggling companies [4][7]. Summary by Sections 1. Performance Outlook - The TCM sector faced overall revenue decline in 2024, with a total revenue of 270.61 billion yuan, down 3.28% year-on-year, and a net profit of 29.88 billion yuan, down 8.55% year-on-year [10]. - The number of companies forecasting negative net profit growth in 2024 is 22 out of 34, while only 12 companies expect positive growth [16]. 2. Policy Developments - The third batch of national TCM procurement results showed an average price reduction of 63%, but the impact on listed companies is limited due to the small number of affected products [20]. - A new essential drug list is expected to be released in 2025, which may include more TCM products, enhancing their market presence [24]. 3. Cost Factors - The TCM material price index has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies and improve their gross margins starting in 2025 [28]. 4. Demand Dynamics - The recent increase in flu cases has driven demand for related treatment products, leading to a quicker clearance of inventory for cold and cough medications [34]. 5. Competitive Landscape - The TCM industry is experiencing frequent mergers and acquisitions, which are likely to enhance industry concentration and provide performance flexibility for related listed companies [39]. 6. Investment Opportunities - The report highlights five key investment themes: 1. High-end OTC TCM products, particularly those using natural bezoar as a key ingredient, are expected to see improved margins as supply stabilizes [45][54]. 2. State-owned enterprise reforms are anticipated to yield positive changes in management and strategic planning [7]. 3. Hospital-based TCM products are expected to gain market share due to regulatory support [7]. 4. Companies with strong cash flow and high dividend potential are viewed favorably [7]. 5. Companies currently facing challenges are expected to improve as inventory pressures ease [7]. 7. Recommended Stocks - The report suggests monitoring companies such as Kunming Pharmaceutical, Tongrentang, Darentang, Jiangzhong Pharmaceutical, Dong'e Ejiao, China Resources Sanjiu, Yunnan Baiyao, Tianshili, Fangsheng Pharmaceutical, and others for potential investment opportunities [4].